These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 16375765

  • 1. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs.
    Liu-Seifert H, Adams DH, Kinon BJ.
    BMC Med; 2005 Dec 23; 3():21. PubMed ID: 16375765
    [Abstract] [Full Text] [Related]

  • 2. Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia.
    Kinon BJ, Liu-Seifert H, Adams DH, Citrome L.
    J Clin Psychopharmacol; 2006 Dec 23; 26(6):632-7. PubMed ID: 17110821
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
    Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, Rosenheck RA, Keefe RS, Miller AL, Belz I, Hsiao JK, CATIE Investigators.
    Am J Psychiatry; 2007 Mar 23; 164(3):415-27. PubMed ID: 17329466
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.
    Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK, CATIE Investigators.
    Am J Psychiatry; 2006 Apr 23; 163(4):611-22. PubMed ID: 16585435
    [Abstract] [Full Text] [Related]

  • 5. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
    Mullins CD, Obeidat NA, Cuffel BJ, Naradzay J, Loebel AD.
    Schizophr Res; 2008 Jan 23; 98(1-3):8-15. PubMed ID: 17596914
    [Abstract] [Full Text] [Related]

  • 6. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.
    Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA, Comparison of Atypicals in First Episode study group.
    J Clin Psychiatry; 2008 Jan 23; 69(1):106-13. PubMed ID: 18312044
    [Abstract] [Full Text] [Related]

  • 7. The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials.
    Kinon BJ, Ascher-Svanum H, Adams DH, Chen L.
    J Clin Psychopharmacol; 2008 Oct 23; 28(5):544-9. PubMed ID: 18794651
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
    Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.
    N Engl J Med; 2005 Sep 22; 353(12):1209-23. PubMed ID: 16172203
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.
    McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowski SD.
    Am J Psychiatry; 2007 Jul 22; 164(7):1050-60. PubMed ID: 17606657
    [Abstract] [Full Text] [Related]

  • 10. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA, CATIE Investigators, Neurocognitive Working Group.
    Arch Gen Psychiatry; 2007 Jun 22; 64(6):633-47. PubMed ID: 17548746
    [Abstract] [Full Text] [Related]

  • 11. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.
    Sacchetti E, Valsecchi P, Parrinello G, QUERISOLA Group.
    Schizophr Res; 2008 Jan 22; 98(1-3):55-65. PubMed ID: 17933497
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L, Meng X, Hochfeld M, Stahl SM.
    Hum Psychopharmacol; 2012 Jan 22; 27(1):24-32. PubMed ID: 22161738
    [Abstract] [Full Text] [Related]

  • 13. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial.
    Gharabawi GM, Greenspan A, Rupnow MF, Kosik-Gonzalez C, Bossie CA, Zhu Y, Kalali AH, Awad AG.
    BMC Psychiatry; 2006 Oct 20; 6():45. PubMed ID: 17054789
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
    Wang X, Savage R, Borisov A, Rosenberg J, Woolwine B, Tucker M, May R, Feldman J, Nemeroff CB, Miller AH.
    J Psychiatr Res; 2006 Oct 20; 40(7):669-76. PubMed ID: 16762371
    [Abstract] [Full Text] [Related]

  • 15. Influence of aging on the improvement of subjective sleep quality by atypical antipsychotic drugs in patients with schizophrenia: comparison of middle-aged and older adults.
    Yamashita H, Mori K, Nagao M, Okamoto Y, Morinobu S, Yamawaki S.
    Am J Geriatr Psychiatry; 2005 May 20; 13(5):377-84. PubMed ID: 15879586
    [Abstract] [Full Text] [Related]

  • 16. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.
    Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Reimherr F, Miller DD, McGee M, Khan A, Canive JM, Davis SM, Hsiao JK, Lieberman JA, CATIE Investigators.
    Schizophr Res; 2008 Mar 20; 100(1-3):39-52. PubMed ID: 18191383
    [Abstract] [Full Text] [Related]

  • 17. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia.
    Keck PE, Strakowski SM, McElroy SL.
    J Clin Psychiatry; 2000 Mar 20; 61 Suppl 3():4-9. PubMed ID: 10724127
    [Abstract] [Full Text] [Related]

  • 18. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
    Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, Reimherr F, McGee MF, Keefe RS, McEvoy JP, Hsiao JK, Lieberman JA, CATIE Investigators.
    Am J Psychiatry; 2007 Mar 20; 164(3):428-36. PubMed ID: 17329467
    [Abstract] [Full Text] [Related]

  • 19. Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia.
    Liu-Seifert H, Osuntokun OO, Feldman PD.
    Compr Psychiatry; 2012 Jan 20; 53(1):107-15. PubMed ID: 21310400
    [Abstract] [Full Text] [Related]

  • 20. Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST).
    Gaebel W, Riesbeck M, von Wilmsdorff M, Burns T, Derks EM, Kahn RS, Rössler W, Fleischhacker WW, EUFEST Study Group.
    Eur Neuropsychopharmacol; 2010 May 20; 20(5):310-6. PubMed ID: 20202800
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.